ADAPTIVE BIOTECHNOLOGIES CORPORATION Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $5.40 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-29.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2024-02-29
- ADAPTIVE BIOTECHNOLOGIES CORPORATION right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $0.00.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-09-30 was $0.00.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $5.40M, a 95.05% decline from fiscal 2020.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $109.10M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $5.40M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $5.40M 10-Q · filed 2021-11-03 | ||
| 2021-06-30 | $5.40M 10-Q · filed 2021-08-04 | |||
| 2020-12-31 | $109.10M 10-K · filed 2023-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |